;PMID: 1536950
;source_file_814.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..31] = [t:0..31]
;1)sentence:[e:36..166] = [t:36..166]
;2)section:[e:170..283] = [t:170..283]
;3)section:[e:287..364] = [t:287..364]
;4)sentence:[e:368..540] = [t:368..540]
;5)sentence:[e:541..712] = [t:541..712]
;6)sentence:[e:713..831] = [t:713..831]
;7)sentence:[e:832..942] = [t:832..942]
;8)sentence:[e:943..1081] = [t:943..1081]
;9)sentence:[e:1082..1204] = [t:1082..1204]
;10)sentence:[e:1205..1320] = [t:1205..1320]
;11)sentence:[e:1321..1437] = [t:1321..1437]
;12)sentence:[e:1438..1661] = [t:1438..1661]
;13)section:[e:1665..1709] = [t:1665..1709]

;section 0 Span:0..31
;Blood  1992 Mar 1;79(5):1266-70
(SEC
  (FRAG (IN:[0..5] Blood) (CD:[7..11] 1992) (NNP:[12..15] Mar) (CD:[16..19] 1;7)
        (CD:[19..20] 9) (NN:[20..21] -LRB-) (NN:[21..22] 5)
        (-RRB-:[22..23] -RRB-) (::[23..24] :) (CD:[24..27] 126)
        (CD:[27..31] 6-70)))

;sentence 1 Span:36..166
;Longitudinal analysis of point mutations of the N-ras proto-oncogene in
;patients  with myelodysplasia using archived blood smears.
;[61..76]:variation-type:"point mutations"
;[84..89]:gene-rna:"N-ras"
;[123..137]:malignancy:"myelodysplasia"
(SENT
  (FRAG-HLN
    (NP
      (NP (JJ:[36..48] Longitudinal) (NN:[49..57] analysis))
      (PP (IN:[58..60] of)
        (NP
          (NP (NN:[61..66] point) (NNS:[67..76] mutations))
          (PP (IN:[77..79] of)
            (NP (DT:[80..83] the) (NN:[84..89] N-ras) (AFX:[90..95] proto)
                (HYPH:[95..96] -) (NN:[96..104] oncogene)))
          (PP-LOC (IN:[105..107] in)
            (NP
              (NP (NNS:[108..116] patients))
              (PP (IN:[118..122] with)
                (NP (NN:[123..137] myelodysplasia))))))))
    (S-MNR
      (NP-SBJ (-NONE-:[137..137] *))
      (VP (VBG:[138..143] using)
        (NP (VBN:[144..152] archived) (NN:[153..158] blood)
            (NNS:[159..165] smears))))
    (.:[165..166] .)))

;section 2 Span:170..283
;van Kamp H, de Pijper C, Verlaan-de Vries M, Bos JL, Leeksma CH, Kerkhofs H, 
;Willemze R, Fibbe WE, Landegent JE.
(SEC
  (FRAG (NNP:[170..173] van) (NNP:[174..178] Kamp) (NNP:[179..181] H,)
        (IN:[182..184] de) (NNP:[185..191] Pijper) (NNP:[192..194] C,)
        (NNP:[195..201] Verlaa) (::[201..205] n-de) (NNP:[206..211] Vries)
        (NNP:[212..214] M,) (NNP:[215..218] Bos) (NNP:[219..221] JL)
        (,:[221..222] ,) (NNP:[223..230] Leeksma) (NNP:[231..234] CH,)
        (NNP:[235..243] Kerkhofs) (NNP:[244..246] H,) (NNP:[248..256] Willemze)
        (NNP:[257..258] R) (,:[258..259] ,) (NNP:[260..265] Fibbe)
        (NNP:[266..268] WE) (,:[268..269] ,) (NNP:[270..279] Landegent)
        (NNP:[280..283] JE.)))

;section 3 Span:287..364
;Department of Hematology, University Medical Center, Leiden, The
;Netherlands.
(SEC
  (FRAG (NNP:[287..297] Department) (IN:[298..300] of)
        (NNP:[301..311] Hematology) (,:[311..312] ,) (NNP:[313..323] University)
        (NNP:[324..331] Medical) (NNP:[332..338] Center) (,:[338..339] ,)
        (NNP:[340..346] Leiden) (,:[346..347] ,) (DT:[348..351] The)
        (NNP:[352..363] Netherlands) (.:[363..364] .)))

;sentence 4 Span:368..540
;We performed a longitudinal analysis of point mutations of the N-ras 
;proto-oncogene in patients with myelodysplasia and a follow-up of at least
;2.5  years after diagnosis.
;[408..423]:variation-type:"point mutations"
;[431..436]:gene-rna:"N-ras"
;[470..484]:malignancy:"myelodysplasia"
(SENT
  (S
    (NP-SBJ (PRP:[368..370] We))
    (VP (VBD:[371..380] performed)
      (NP
        (NP
          (NP (DT:[381..382] a) (JJ:[383..395] longitudinal)
              (NN:[396..404] analysis))
          (PP (IN:[405..407] of)
            (NP
              (NP (NN:[408..413] point) (NNS:[414..423] mutations))
              (PP (IN:[424..426] of)
                (NP (DT:[427..430] the) (NN:[431..436] N-ras)
                    (AFX:[438..443] proto) (HYPH:[443..444] -)
                    (NN:[444..452] oncogene)))
              (PP-LOC (IN:[453..455] in)
                (NP
                  (NP (NNS:[456..464] patients))
                  (PP (IN:[465..469] with)
                    (NP (NN:[470..484] myelodysplasia))))))))
        (CC:[485..488] and)
        (NP
          (NP (DT:[489..490] a) (NN:[491..500] follow-up))
          (PP (IN:[501..503] of)
            (NP
              (NP
                (QP (IN:[504..506] at) (JJS:[507..512] least)
                    (CD:[513..516] 2.5))
                (NNS:[518..523] years))
              (PP-TMP (IN:[524..529] after)
                (NP (NN:[530..539] diagnosis))))))))
    (.:[539..540] .)))

;sentence 5 Span:541..712
;Point mutations at codons 12, 13, and 61 of the N-ras  oncogene were analyzed
;after in vitro amplification of N-ras specific sequences  followed by
;dot-blot hybridization.
;[541..556]:variation-type:"Point mutations"
;[560..569]:variation-location:"codons 12"
;[560..566]...[579..581]:variation-location:"codons"..."61"
;[560..566]...[571..573]:variation-location:"codons"..."13"
;[589..594]:gene-rna:"N-ras"
;[651..656]:gene-rna:"N-ras"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[541..546] Point) (NNS:[547..556] mutations))
      (PP-LOC (IN:[557..559] at)
        (NP
          (NP
            (NP
              (NML-1 (NNS:[560..566] codons))
              (CD:[567..569] 12))
            (,:[569..570] ,)
            (NP
              (NML-1 (-NONE-:[570..570] *P*))
              (CD:[571..573] 13))
            (,:[573..574] ,) (CC:[575..578] and)
            (NP
              (NML-1 (-NONE-:[578..578] *P*))
              (CD:[579..581] 61)))
          (PP (IN:[582..584] of)
            (NP (DT:[585..588] the) (NN:[589..594] N-ras)
                (NN:[596..604] oncogene))))))
    (VP (VBD:[605..609] were)
      (VP (VBN:[610..618] analyzed)
        (NP-2 (-NONE-:[618..618] *))
        (PP-TMP (IN:[619..624] after)
          (NP
            (NP
              (NP
                (ADJP (FW:[625..627] in) (FW:[628..633] vitro))
                (NN:[634..647] amplification))
              (PP (IN:[648..650] of)
                (NP
                  (ADJP (NN:[651..656] N-ras) (JJ:[657..665] specific))
                  (NNS:[666..675] sequences))))
            (VP (VBN:[677..685] followed)
              (NP (-NONE-:[685..685] *))
              (PP (IN:[686..688] by)
                (NP
                  (NML (NN:[689..692] dot) (HYPH:[692..693] -)
                       (NN:[693..697] blot))
                  (NN:[698..711] hybridization))))))))
    (.:[711..712] .)))

;sentence 6 Span:713..831
;Lysed cells scraped from archived blood and  bone marrow smears were used as
;template for a polymerase chain reaction.
;[805..815]:gene-protein:"polymerase"
(SENT
  (S
    (NP-SBJ-1
      (NP (VBN:[713..718] Lysed) (NNS:[719..724] cells))
      (VP (VBN:[725..732] scraped)
        (NP (-NONE-:[732..732] *))
        (PP (IN:[733..737] from)
          (NP
            (NP
              (ADJP-2 (VBN:[738..746] archived))
              (NN:[747..752] blood)
              (NML-3 (-NONE-:[752..752] *P*)))
            (CC:[753..756] and)
            (NP
              (ADJP-2 (-NONE-:[756..756] *P*))
              (NML (NN:[758..762] bone) (NN:[763..769] marrow))
              (NML-3 (NNS:[770..776] smears)))))))
    (VP (VBD:[777..781] were)
      (VP (VBN:[782..786] used)
        (NP-1 (-NONE-:[786..786] *))
        (PP (IN:[787..789] as)
          (NP
            (NP (NN:[790..798] template))
            (PP (IN:[799..802] for)
              (NP (DT:[803..804] a) (NN:[805..815] polymerase)
                  (NN:[816..821] chain) (NN:[822..830] reaction)))))))
    (.:[830..831] .)))

;sentence 7 Span:832..942
;In 3  of 90 patients tested (3.3%), a mutation in codon 12 could be detected
;in the  most recent blood smears.
;[870..878]:variation-event:"mutation"
;[882..890]:variation-location:"codon 12"
(SENT
  (S
    (PP (IN:[832..834] In)
      (NP
        (NP (CD:[835..836] 3))
        (PP (IN:[838..840] of)
          (NP
            (NP (CD:[841..843] 90) (NNS:[844..852] patients))
            (VP (VBN:[853..859] tested)
              (NP-SBJ (-NONE-:[859..859] *))
              (PRN (-LRB-:[860..861] -LRB-)
                (NP (CD:[861..864] 3.3) (NN:[864..865] %))
                (-RRB-:[865..866] -RRB-)))))))
    (,:[866..867] ,)
    (NP-SBJ-1
      (NP (DT:[868..869] a) (NN:[870..878] mutation))
      (PP-LOC (IN:[879..881] in)
        (NP (NN:[882..887] codon) (CD:[888..890] 12))))
    (VP (MD:[891..896] could)
      (VP (VB:[897..899] be)
        (VP (VBN:[900..908] detected)
          (NP-1 (-NONE-:[908..908] *))
          (PP (IN:[909..911] in)
            (NP (DT:[912..915] the)
              (ADJP (RBS:[917..921] most) (JJ:[922..928] recent))
              (NN:[929..934] blood) (NNS:[935..941] smears))))))
    (.:[941..942] .)))

;sentence 8 Span:943..1081
;All available blood and bone marrow samples of these  patients were
;subsequently analyzed for the occurrence of that particular  mutation.
;[1072..1080]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[943..946] All) (JJ:[947..956] available)
        (NML
          (NML (NN:[957..962] blood)
            (NML-1 (-NONE-:[962..962] *P*)))
          (CC:[963..966] and)
          (NML (NN:[967..971] bone) (NN:[972..978] marrow)
            (NML-1 (NNS:[979..986] samples)))))
      (PP (IN:[987..989] of)
        (NP (DT:[990..995] these) (NNS:[997..1005] patients))))
    (VP (VBD:[1006..1010] were)
      (ADVP-TMP (RB:[1011..1023] subsequently))
      (VP (VBN:[1024..1032] analyzed)
        (NP-2 (-NONE-:[1032..1032] *))
        (PP (IN:[1033..1036] for)
          (NP
            (NP (DT:[1037..1040] the) (NN:[1041..1051] occurrence))
            (PP (IN:[1052..1054] of)
              (NP (DT:[1055..1059] that) (JJ:[1060..1070] particular)
                  (NN:[1072..1080] mutation)))))))
    (.:[1080..1081] .)))

;sentence 9 Span:1082..1204
;In all three cases the mutation was not detectable at diagnosis, but  was
;acquired later during the course of the disease.
;[1105..1113]:variation-event:"mutation"
;[1196..1203]:malignancy:"disease"
(SENT
  (S
    (PP (IN:[1082..1084] In)
      (NP (DT:[1085..1088] all) (CD:[1089..1094] three) (NNS:[1095..1100] cases)))
    (NP-SBJ-1 (DT:[1101..1104] the) (NN:[1105..1113] mutation))
    (VP
      (VP (VBD:[1114..1117] was) (RB:[1118..1121] not)
        (ADJP-PRD (JJ:[1122..1132] detectable))
        (PP-TMP (IN:[1133..1135] at)
          (NP (NN:[1136..1145] diagnosis))))
      (,:[1145..1146] ,) (CC:[1147..1150] but)
      (VP (VBD:[1152..1155] was)
        (VP (VBN:[1156..1164] acquired)
          (NP-1 (-NONE-:[1164..1164] *))
          (ADVP-TMP (RB:[1165..1170] later))
          (PP-TMP (IN:[1171..1177] during)
            (NP
              (NP (DT:[1178..1181] the) (NN:[1182..1188] course))
              (PP (IN:[1189..1191] of)
                (NP (DT:[1192..1195] the) (NN:[1196..1203] disease))))))))
    (.:[1203..1204] .)))

;sentence 10 Span:1205..1320
;In two of these patients  this event was associated with rapid deterioration
;and transformation to acute  leukemia.
;[1304..1319]:malignancy:"acute  leukemia"
(SENT
  (S
    (PP (IN:[1205..1207] In)
      (NP
        (NP (CD:[1208..1211] two))
        (PP (IN:[1212..1214] of)
          (NP (DT:[1215..1220] these) (NNS:[1221..1229] patients)))))
    (NP-SBJ-1 (DT:[1231..1235] this) (NN:[1236..1241] event))
    (VP (VBD:[1242..1245] was)
      (VP (VBN:[1246..1256] associated)
        (NP-1 (-NONE-:[1256..1256] *))
        (PP-CLR (IN:[1257..1261] with)
          (NP
            (NP (JJ:[1262..1267] rapid) (NN:[1268..1281] deterioration))
            (CC:[1282..1285] and)
            (NP
              (NP (NN:[1286..1300] transformation))
              (PP (TO:[1301..1303] to)
                (NP (JJ:[1304..1309] acute) (NN:[1311..1319] leukemia))))))))
    (.:[1319..1320] .)))

;sentence 11 Span:1321..1437
;However, the third patient showed a protracted course during a period  of 5
;years after acquisition of the mutation.
;[1428..1436]:variation-event:"mutation"
(SENT
  (S
    (ADVP (RB:[1321..1328] However))
    (,:[1328..1329] ,)
    (NP-SBJ (DT:[1330..1333] the) (JJ:[1334..1339] third)
            (NN:[1340..1347] patient))
    (VP (VBD:[1348..1354] showed)
      (NP (DT:[1355..1356] a) (JJ:[1357..1367] protracted)
          (NN:[1368..1374] course))
      (PP-TMP (IN:[1375..1381] during)
        (NP
          (NP (DT:[1382..1383] a) (NN:[1384..1390] period))
          (PP (IN:[1392..1394] of)
            (NP
              (NP (CD:[1395..1396] 5) (NNS:[1397..1402] years))
              (PP-TMP (IN:[1403..1408] after)
                (NP
                  (NP (NN:[1409..1420] acquisition))
                  (PP (IN:[1421..1423] of)
                    (NP (DT:[1424..1427] the) (NN:[1428..1436] mutation))))))))))
    (.:[1436..1437] .)))

;sentence 12 Span:1438..1661
;These results indicate that  activation of the N-ras protooncogene in these
;three patients represents a  secondary phenomenon associated with disease
;progression in some cases, but  compatible with stable disease in others.
;[1485..1490]:gene-rna:"N-ras"
;[1580..1587]:malignancy:"disease"
;[1636..1650]:malignancy:"stable disease"
(SENT
  (S
    (NP-SBJ (DT:[1438..1443] These) (NNS:[1444..1451] results))
    (VP (VBP:[1452..1460] indicate)
      (SBAR (IN:[1461..1465] that)
        (S
          (NP-SBJ
            (NP (NN:[1467..1477] activation))
            (PP (IN:[1478..1480] of)
              (NP (DT:[1481..1484] the) (NN:[1485..1490] N-ras)
                  (NN:[1491..1504] protooncogene)))
            (PP-LOC (IN:[1505..1507] in)
              (NP (DT:[1508..1513] these) (CD:[1514..1519] three)
                  (NNS:[1520..1528] patients))))
          (VP (VBZ:[1529..1539] represents)
            (NP
              (NP (DT:[1540..1541] a) (JJ:[1543..1552] secondary)
                  (NN:[1553..1563] phenomenon))
              (ADJP
                (ADJP (JJ:[1564..1574] associated)
                  (PP (IN:[1575..1579] with)
                    (NP (NN:[1580..1587] disease) (NN:[1588..1599] progression)))
                  (PP (IN:[1600..1602] in)
                    (NP (DT:[1603..1607] some) (NNS:[1608..1613] cases))))
                (,:[1613..1614] ,) (CC:[1615..1618] but)
                (ADJP (JJ:[1620..1630] compatible)
                  (PP (IN:[1631..1635] with)
                    (NP (JJ:[1636..1642] stable) (NN:[1643..1650] disease)))
                  (PP (IN:[1651..1653] in)
                    (NP (NNS:[1654..1660] others))))))))))
    (.:[1660..1661] .)))

;section 13 Span:1665..1709
;PMID: 1536950 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1665..1669] PMID) (::[1669..1670] :) (CD:[1671..1678] 1536950)
        (NN:[1679..1680] -LSB-) (NNP:[1680..1686] PubMed) (::[1687..1688] -)
        (NN:[1689..1696] indexed) (IN:[1697..1700] for)
        (NNP:[1701..1709] MEDLINE-RSB-)))
